To Study the Safety and Efficacy of Midodrine With Albumin Versus Albumin Alone in Hepatic Hydrothorax
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
Hepatic hydrothorax is defined with accumulation of transudate fluid (500 ml) in the pleural
cavity in patients with decompensated liver cirrhosis but without cardiopulmonary and pleural
diseases. The Prevalence is 5-12% The treatment for hydrothorax is diuretics, repeated
thoracocentensis, TIPS and liver transplant.. Midodrine increases effective arterial blood
volume and also increases renal perfusion.It has also been used in Refractory ascitis .It has
been shown to mobilise ascitis. In patients who are ineligible for TIPS and Liver transplant
there is no data on Midodrine and its effects on Hydrothorax in cirrhotics.There are also no
guidelines on the use of albumin during Pleural fluid tapping and the dose to be used. This
study is being done to assess the safety and efficacy of Midodrine in hydrothorax.